Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPHETIC study of JAK inhibitor pharmacokinetics and biomarkers in ulcerative colitis
NL-OMON54935Active, not recruiting
- Sponsor
- Alimentiv Inc.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofacitinib, filgotinib, upadacitinib and izencitinib in autoimmune colitis, sponsored by Alimentiv Inc. Primary endpoints: Baseline predictive biomarkers associated with UC-100 change, Pharmacodynamic biomarkers associated with UC-100 change and 9 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON54935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54935.